Major Biotech Short Interest Continues to Be Mixed
The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of the selected biotech stocks.
The short interest data are out for the January 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of these selected stocks for this settlement date.
Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.41 million shares from the previous level of 9.03 million. Shares closed most recently at $143.16, in a 52-week trading range of $130.09 to $181.81.
Biogen Inc. (NASDAQ: BIIB) had its short interest decrease slightly to 2.76 million from the previous level of 2.85 million. Shares closed Tuesday at $249.99, within a 52-week range of $243.85 to $480.18.
Celgene Corp. (NASDAQ: CELG) short interest for this settlement date increased to 10.50 million shares from the previous 9.06 million. Shares of Celgene closed most recently at $100.50, in a 52-week range of $92.98 to $140.72.
[recirclink id=314080]
Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest fall to 21.37 million shares from 23.16 million in the previous period. Shares closed Tuesday at $87.25, in a 52-week trading range of $81.89 to $123.37.
MannKind Corp. (NASDAQ: MNKD) saw its short interest increase to 124.41 million shares. The previous reading was 123.89 million. Shares closed most recently at $0.97, in a 52-week trading range of $0.64 to $7.88.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest decreased to 5.47 million, compared to the
previous level of 5.65 million. Shares closed most recently at $136.46, in a 52-week range of $130.51 to $208.88.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
